The
effectiveness of a therapeutic agent for cancer stands in its
ability to reduce and eliminate tumors without harming the healthy
tissue nearby. Nanoparticles peripherally conjugated with targeting
moieties offer major improvements in therapeutics through site specificity.
In this study we demonstrate this approach by targeting the folate
receptor of NIH:OVCAR-3 human ovary cancer cell line. Herein we used
silver nanotriangles which were biocompatibilized with chitosan (bio)polymer,
labeled with para-aminothiophenol (pATP) Raman reporter molecule,
and conjugated with folic acid. The nanoparticles conjugation and
efficient labeling was investigated by localized surface plasmon resonance
(LSPR), zeta potential, and surface-enhanced Raman scattering (SERS)
measurements. Conjugated particles were proven to be highly stable
in aqueous and cellular medium. The targeted uptake of conjugated
nanoparticles by human ovary cancer cells was confirmed by dark field
microscopy and scattering spectra of the particles inside cells. Comparative
studies revealed specific internalization of the conjugated nanoparticles
in comparison with similar bare nanoparticles. Moreover, the SERS
identity of the particles was proven to be highly conserved inside
cells. Targeted cancer cell treatment conducted by irradiating the
nanoparticle-treated cells with a continuous wave-nearinfrared (cw-NIR)
laser in resonance with their plasmonic band proved an efficient therapeutic
response. By integrating the advantages of multimodal optical imaging
and SERS detection with hyperthermia capabilities through site specificity,
these nanoparticles can represent a real candidate for personalized
medicine.